48 citations
,
March 1997 in “Veterinary Dermatology” This report describes a paraneoplastic alopecia in four cats associated with internal malignancy, confirming previous findings of a syndrome linking ventral alopecia and metastatic carcinomas.
52 citations
,
January 1999 in “Journal of Small Animal Practice” This case study of a cat with pancreatic carcinoma and paraneoplastic alopecia found that removing the internal tumor reversed hair loss, but symptoms reappeared as the cancer metastasized.
October 2020 in “Our Dermatology Online” This report presents two cases where dermatologists identified internal malignancies—small cell lung cancer and stage IIB cervical cancer—through paraneoplastic skin manifestations.
November 2013 in “International Journal of Dermatology” New skin lesions on the scrotum or vulva in patients with a history of internal cancer could indicate rare skin metastasis.
2 citations
,
May 2025 in “Archives of Dermatological Research” This retrospective cohort study found no significant association between Janus kinase inhibitors and increased malignancy risk in alopecia areata patients, but traditional immunosuppressants were linked to higher risks of internal and hematologic malignancies.
105 citations
,
December 2003 in “Veterinary Dermatology” This review discusses the association between cutaneous paraneoplastic syndromes and internal malignancies, noting that recognition of these skin disorders may help detect underlying cancers, but reports no new research findings.
43 citations
,
November 2007 in “Dermatologic Clinics” This article discusses various hair and nail abnormalities linked to paraneoplastic conditions and cancer treatments, emphasizing their potential role in diagnosing and managing internal malignancies and reports no new clinical findings.
38 citations
,
July 1998 in “Journal of surgical oncology” This review discusses acquired hypertrichosis lanuginosa, a rare disorder often linked to internal malignancy, and reports no new clinical findings; the authors highlight proposed pathogenic mechanisms for lanugo hair overgrowth.
March 2005 in “Journal of the American Academy of Dermatology” Recognizing minor skin lesions can help identify serious cancer syndromes.
3 citations
,
March 1998 in “PubMed” This case report describes a 70-year-old woman whose acquired ichthyosis resolved and darker hair regrew after removing a leiomyosarcoma, highlighting a possible association between the two conditions.
January 2011 in “Elsevier eBooks” Alopecia in animals can be hereditary, congenital, or acquired, with treatments and outcomes varying widely.
March 1998 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study reported that acquired ichthyosis and hair changes in a 70-year-old woman with leiomyosarcoma resolved after the surgical removal of the tumor.
May 2019 in “Small Animal Dermatology” This chapter discusses a case of feline paraneoplastic alopecia in a cat and provides educational insights into recognizing and managing the condition, along with potential treatment approaches.
August 2024 in “Research Square (Research Square)” This study found that women taking 5α-reductase inhibitors (5aRI) for alopecia had a lower risk of breast cancer compared to those not using these medications, with no increased risk of developing ovarian or endometrial cancer.
June 2026 in “Current Oncology Reports” This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” This review discusses topical calcineurin inhibitors for cutaneous lupus erythematosus and reports no new clinical findings; the authors emphasize the need for more comparative studies with corticosteroids.
60 citations
,
September 2013 in “Alimentary Pharmacology & Therapeutics” This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.
68 citations
,
June 2005 in “Expert Opinion on Therapeutic Targets” This review discusses the influence of oestrogens on various skin components and highlights their modulatory roles and receptor pathways, but it reports no new clinical results.
60 citations
,
May 2015 in “Archives of dermatological research” This review discusses the role of peroxisome proliferator-activated receptors and their agonists in dermatology but reports no new clinical results.
22 citations
,
October 2018 in “British Journal of Haematology” This review examines the gender-specific challenges in preventing and treating venous thromboembolism in women and highlights the need for further research on safe and optimal treatment strategies.
June 2020 in “International Journal of Research in Dermatology” In this study, xerosis was the most common skin condition found among elderly participants, followed by wrinkling and immunoglobulin heavy chain deposition.
39 citations
,
October 2014 in “Schweizerische medizinische Wochenschrift” This study found that while cyclophosphamide remains effective for severe autoimmune conditions, it is associated with gastrointestinal side effects, infections, some cases of irreversible amenorrhoea, and a higher risk of malignancies, emphasizing the need for long-term monitoring.
6 citations
,
December 2018 in “Medical principles and practice” This meta-analysis reported that individuals who frequently use hair dye or have used it for over 20 years have an increased risk of developing non-Hodgkin's lymphoma.
July 2025 in “SKIN The Journal of Cutaneous Medicine” This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.
January 2024 in “American journal of clinical dermatology” This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.
May 2025 in “Acta Dermato Venereologica” This study found that individuals with hospital-treated alopecia areata in Denmark had increased standardized incidence rates of serious infections, herpes zoster infections, lymphoma, cardiovascular events, and death compared to the age- and sex-matched general population.
8 citations
,
October 2021 in “Journal of Mind and Medical Sciences” This review emphasizes the importance of identifying and modifying patient-related risk factors to reduce morbidity and mortality after gastric cancer surgeries but presents no new clinical findings.
233 citations
,
March 2009 in “Journal of Clinical Oncology” In this study, among patients undergoing chemotherapy for breast or gynecologic cancers, smell and taste functions significantly decreased but largely recovered three months post-treatment, with taxane-based regimens causing more severe taste disturbances.
May 2023 in “Dermatology Online Journal” No increased skin cancer risk was found in alopecia patients treated with photobiomodulation.
April 2026 in “The Journal of Dermatology” This study found that patients with vitiligo in the United States had higher rates of autoimmune conditions, infections, and skin cancer compared to matched controls, with higher vitiligo prevalence in Asian and Hispanic populations.